Hematologic Malignancy
Plasma Cell Leukemia
CI-CAN-00001421PCLExplore in graph →
Hematologic23 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001421PCLExplore in graph →
Clinical trials
53 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | recruiting | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07652905 | CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia(CAREMM-011) | recruiting | Phase 2 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 |
| NCT03389347 | High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | N/A | 40 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05283993 | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | recruiting | — | 2,000 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06517017 | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma(UltraFrailMM) | recruiting | Phase 2 | 40 | University of UtahOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study(NIMMS) | recruiting | — | 400 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level(iFIT) | recruiting | Phase 3 | 1,226 | University of LeedsOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05870917 | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia | active not recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05405387 | Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant(IMPACT) | recruiting | Phase 2 | 120 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02334865 | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | active not recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07509086 | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia | recruiting | Phase 2 | 25 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT05556928 | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry(CARE-Heme) | recruiting | — | 5,000 | University of Alabama at BirminghamOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT03717844 | Registry for Adults With Plasma Cell Disorders (PCD's) | recruiting | — | 2,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07109323 | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05979363 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia(CAREMM-002) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06988059 | A Study of CT0596 in Plasma Cell Leukemia | recruiting | Early Phase 1 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07085559 | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | recruiting | Early Phase 1 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 25, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05219721 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 18 | Chunrui LiOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05759793 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT01729091 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06830733 | Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia(GEM-PLASMACAR) | not yet recruiting | Phase 2 | 25 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT01163357 | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT02506959 | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT02547662 | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05893693 | Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 12 | Aibin Liang，MD，Ph.D.OTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05822037 | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 6 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT05054478 | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation(PCL-2) | not yet recruiting | Phase 2 | 29 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 23, 2021 | clinicaltrials |
| NCT02504359 | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | completed | Phase 1 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01372540 | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04008888 | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | unknown | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01008462 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03591744 | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials